Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Vita Bella

AM Rx
Graded #491

Lower grade

vs+14.999999999999993
Vita Bella
Graded #242

Higher grade

The verdict

Vita Bella takes it — 64.6/100 to 49.6/100.

Vita Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vita Bella is a Nevada-based telehealth membership platform (Vita Bella Health, LLC) that offers compounded GLP-1 weight-loss medications alongside hormone therapy, peptides, sexual-wellness and anti-aging…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +7
50
43
Dose & formulationAM Rx +13
65
52
Clinical oversightVita Bella +50
41
91
Labs & monitoringVita Bella +28
49
77
FulfillmentVita Bella +25
58
83
Contract termsVita Bella +27
20
47
AM Rx · left barVita Bella · right bar

The numbers

MetricAM RxVita Bella
WeighScore49.6/10064.6/100
GradeCC
Scorecard rank#491#242
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosed$159/mo (2.5 mg dose, plus a separate fee, compounded)
CoverageCoverage not published46 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Vita Bella

Graded #242 · C

Strengths

  • Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
  • Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
  • Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
  • Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
  • Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge

Where it loses points

  • Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
  • Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
  • Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard